SERA Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Net Revenue: $16,000 for Q3 2025, down from $29,000 in Q3 2024.
Operating Expenses: Totaled $9,000,000, slightly up from $8,900,000 year-over-year.
- R&D Expenses: $3,300,000, down from $3,500,000, reflecting reduced clinical study costs.
- SG&A Expenses: Increased to $5,700,000 from $5,400,000 due to investments in commercial activities.
Net Loss: $7,800,000, a slight improvement from $7,900,000 in the previous year.
Cash Position: Approximately $102,400,000 as of September 30, 2025.

2. Strategic Updates and Business Highlights

Commercialization Strategy: Focused on geographic regions with favorable conditions for preterm test adoption, including Medicaid pilot programs in Nevada and five other states.
PRIME Study: Progressing towards publication of full results by year-end, with ongoing presentations at industry conferences to build visibility.
Leadership Appointments: New Chief Medical Officer, Dr. Tiffany Inglis, and Head of Commercial Operations, Merisol Urano, to drive adoption and integration of the preterm test.
Pilot Programs: Active enrollment in the Nevada Medicaid pilot, with plans for additional pilots in other states.

3. Forward Guidance and Outlook

Publication of PRIME Study: Expected by the end of 2025, which will trigger broader payer engagement and coverage discussions.
Timeline for Guideline Inclusion: Estimated 24 to 36 months post-publication for potential guideline updates.
Sales Force Expansion: Plans to increase sales representatives in alignment with successful pilot programs and state engagement.

4. Bad News, Challenges, or Points of Concern

Revenue Decline: Significant drop in net revenue year-over-year raises concerns about immediate financial performance.
Long Path to Coverage: The anticipated 24-month cycle for Medicaid coverage decisions may delay revenue generation.
Pilot Program Limitations: The size and scope of pilot programs may limit immediate impact and revenue realization.
Market Competition: The need to establish a strong foothold in a competitive landscape for prenatal testing.

5. Notable Q&A Insights

Pilot Progress: Management confirmed they are on track with pilot programs, with one live and another in contracting, and discussions ongoing with additional states.
Economic Viability: Positive price realization in early payer engagements, though specifics were not disclosed.
Organizational Readiness: The company is prepared for the PRIME publication, with strategies in place for payer engagement and clinician education.
Sales and Marketing Focus: Anticipated increase in SG&A expenses for 2026, particularly in sales and marketing, while overall expenses are expected to remain stable.

Overall, SERA is making strides in its commercialization efforts and preparing for the critical publication of the PRIME study, although it faces challenges related to revenue generation and the lengthy process of achieving Medicaid coverage.

SERA — Sera Prognostics, Inc.